Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study

Nivolumab alleviates symptom burden and improves health status versus docetaxel as second-line squamous NSCLC treatment.